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A central idea underlying the INTEGRATE-HTA project is that
many of the interventions that are being used in health care
are quite complex. By this, we mean that the relation between
the delivery of the intervention on the one hand, and the on-
set of (desired and undesired) changes may be less straight-
forward than hoped for. There may be all sorts of reasons
for this, varying from a lack of resources, lack of skills, per-
verse incentives, organizational problems, etc. Not identifying
such factors and their potential impact may seriously com-
promise the policy relevance of a health technology assess-
ment (HTA) (1). However, current approaches and methods in
HTA do not seem to be adequately geared to deal with this
complexity.
The INTEGRATE-HTA project has developed and tested
several tools that can assist HTA researchers in exploring com-
plexity and its possible implications for health interventions. A
scoping exercise, conducted at the start of an HTA and involv-
ing the various relevant stakeholders, may help to identify po-
tential sources of complexity and provide guidance to areas for
further inquiry. Developing logic models may help to synthe-
size the various understandings of the relevant issues involved,
graphically representing how interventions are thought to re-
sult in possible outcomes, spelling out what contextual factors
are thought to moderate these processes, in what way, to what
extent, and under what conditions. Any indications for inter-
dependencies may then be the subject of further inquiry, and
findings can be shared with organizations commissioning HTA.
The question is, however: could such an approach be incorpo-
rated in the workflow of HTA agencies, and would it fit within
their remit?
A fact of life is that HTA agencies are faced with mount-
ing pressure to deliver within increasingly tight time schedules,
and commissioning organizations may not have the patience to
wait for the results of more extensive analyses. Stakeholder in-
volvement may enhance the policy relevance of an HTA and
the legitimacy of subsequent policy decisions, but it will al-
most certainly increase the lead time of an HTA. In other words,
does the INTEGRATE-HTA guidance take sufficient account of
the complexity of real-world HTA? Or does it reflect an ideal
that is of academic interest, but impossible to implement in
practice?
To explore those issues, we organized an INAHTA (In-
ternational Network of Agencies for Health Technology As-
sessment) webinar on INTEGRATE-HTA, in which colleagues
from the Canadian Agency for Drugs and Health Technolo-
gies shared their experiences with using the guidance devel-
oped in the INTEGRATE-HTA project. See for more informa-
tion, the article presented in this theme issue (2). Furthermore,
a delegation of the INTEGRATE-HTA team (the authors of this
contribution) paid a visit to one of the national HTA agencies
in Europe, the Belgian Health Care Knowledge Centre (KCE)
and had an interview with two members of the staff. The KCE
participates in EUnetHTA, being the co-lead partner of quality
management, scientific guidance and tools in this consortium.
As such, we believe that their perspective on the INTEGRATE-
HTA project may be reflective of HTA agencies more generally,
particularly in Europe. Below, we present a summary of the in-
terview to indicate if and how the guidance of INTEGRATE-
HTA could be of relevance and adopted in their work
process.
We: Could you briefly describe your organization?
KCE: The KCE consists of a team of ca. sixty people, among
which more than forty researchers. Its mission is to advise, on
the basis of scientific analyses, policy makers on decisions re-
lating to health care and health insurance. Its role is to identify
the best possible solutions for prespecified health care prob-
lems, taking into account accessibility, quality, a growing de-
mand and budgetary constraints. Furthermore, KCE supports
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care providers by developing clinical guidelines, gearing these
toward the evolving body of scientific knowledge and publish-
ing on methodologies that serve as a guide for other health care
researchers (for further details, see kce.fgov.be).
We: Do you recognize the rationale of the INTEGRATE-HTA
project, the complexity of health interventions, and its
implications for HTA?
KCE: Yes, we do. For example, KCE recently launched a re-
port on the evaluation and management of low back pain and
radicular pain. We concluded that there are important opportu-
nities for improving the quality and efficiency of care for these
patients. At the same time, we do recognize some key barriers.
For instance, health care professionals will need more training
in stratifying patients into different risk categories. Also, pa-
tients’ expectations may thwart necessary changes. They may
demand imaging, and it may be very difficult for healthcare
professionals to resist such demands. A paradigm shift from
a biomedical to a biopsychosocial approach is needed, and
this will take time. In addition, multidisciplinary programs
are needed, and patients should be encouraged to continue
daily activities, including work. Hence, although the evidence
concerning the effectiveness of specific health care programs
seems to be fairly straightforward, allowing for the develop-
ment of guidelines, implementation of such guidelines will be
challenging.
We: Do you think the INTEGRATE-HTA could be useful in meeting
those challenges?
KCE: We do acknowledge the importance of stakeholder in-
volvement in HTA. This seems to be one of the elements of
the INTEGRATE-HTA approach, most prominently in its guid-
ance on scoping. We also are investing a lot in stakeholder
involvement, and our general impression is that it may en-
hance support for and uptake of guidelines. However, there
is always a trade-off, and an increased expenditure of time
and resources needs to be balanced with anticipated benefits.
In addition, the guidance on building logic models could be
useful.
It is akin to the infographics that we increasingly use to
summarize the main findings of our analyses. It allows you to
graphically represent processes, work flows, ideas about mech-
anisms, etc. We used them in a report on multi-criteria decision
analysis (MCDA), to summarize current processes for early
temporary reimbursement, and to summarize the MCDA pro-
cess itself. For us, conceptually, the most appealing elements
of the INTEGRATE-HTA project are complexity, multidimen-
sionality, and context (A similar point is made by Bond and
Weeks, who have been using the INTEGRATE-HTA guidance
at the Canadian Agency for Drugs and Technologies in Health
(CADTH) (2).
We: What do you consider the major challenges for HTA in the
near future, and how might INTEGRATE-HTA help to meet those
challenges?
KCE: A key challenge is to do more work in less time. We do
not see how INTEGRATE-HTA helps to meet that challenge.
Secondly, we are seeing a shift from traditional HTA toward
what we would call Health Services Research (HSR). The dif-
ference being that the research question shifts from ”What are
the relevant aspects of this health technology that need to be
taken into account to inform a decision?“ (= HTA) to “How
will this health technology affect the system and the health
prospects of the population?” (= HSR). We think that this is
an important, indeed desirable, change, resulting in outcomes
that are more useful and relevant to policymakers.
In a way, we have to return to the original concept of HTA,
as formulated by for instance David Banta, emphasizing that
HTA is a type of policy research, identifying and evaluating dif-
ferent policy options (3). However, this is clearly a much more
complex task, also setting different demands on the researchers.
It would be important to redirect HTA educational programs
to better prepare a future generation of HTA researchers to
face those challenges. we think that INTEGRATE-HTA defi-
nitely has something to offer here, both in terms of method-
ology, and in terms of thinking about health and healthcare
(conceptually).
Finally, we have to admit that we are still struggling with
ethics. The mission of KCE is to produce useful, intelligent and
completely state-of-the-art analyses of complex health(care)
problems, to indicate potential solutions, and to provide an
overview of the relative advantages and disadvantages that are
associated with those solutions. We cannot, nor desire, make
those decisions ourselves. Can we, at KCE, inform policy mak-
ers about the ethical implications of various policy options, in
a way that is nondirective? So far, we have been experiment-
ing with the accountability for reasonableness approach, de-
veloped by Norman Daniels (4). We found this useful, but do
see its limitations. We would be interested to see whether the
INTEGRATE-HTA has something to offer here that could help
us in navigating between “being insufficient” and “overreach-
ing,” as Norman Daniels put it (5).
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